丙酸睪丸酮在高強度聚焦超聲治療子宮腺肌病中的應用價值
[Abstract]:Background: adenomyosis is a common benign disease in women of childbearing age. Its clinical manifestations are progressive aggravation of dysmenorrhea, menorrhagia, infertility and so on. The recurrence rate of conservative surgical treatment is high because of its unclear boundary and no capsule, which has always been a difficult problem for clinicians. High intensity focused ultrasound (HIFU) makes use of the penetrating and focusing properties of ultrasound to cause coagulation necrosis of the target tissue, thus achieving the purpose of treating tumor. As a noninvasive treatment method, HIFU can significantly improve dysmenorrhea in patients with adenomyosis. Menstruation and other clinical symptoms, but the ovarian endocrine function has little impact. Testosterone propionate is a androgen drug that reduces or suppresses estrogen levels, causes ectopic endometrial atrophy and uterine vasoconstriction. Improved treatment efficiency provides the possibility. The purpose of this study was to investigate the role and safety of testosterone propionate in the treatment of adenomyosis with HIFU. Objective: to evaluate the value of testosterone propionate in the treatment of adenomyosis with HIFU. Materials and methods: 62 cases of adenomyosis treated by HIFU in Fuling Central Hospital of Chongqing were retrospectively analyzed. The treatment time, irradiation time and (EEF), ablation rate of energy efficiency factor were compared between the testosterone propionate group and the control group. To evaluate the safety of HIFU in the treatment of adenomyosis. Results: there was no significant difference in treatment time, irradiation time, EEF and ablation rate between testosterone propionate group and control group. In the testosterone propionate group, 80% (32 / 40) of the lesions had mass gray changes, while 50% (11 / 22) in the control group. The results showed that the probability of mass gray scale change in testosterone propionate group was significantly higher than that in control group (蠂 ~ 2 = 6.010 ~ P ~ (0.014). However, there was no significant difference between the two groups in the time of mass gray change (t0. 613, P < 0. 542). There were no serious side effects in both groups. Conclusion: 1. Testosterone propionate can not effectively enhance the efficiency of HIFU in the treatment of adenomyosis, but it is significant to increase the probability of mass gray level, which is beneficial to the monitoring of HIFU therapy. 2. HIFU is safe and effective in the treatment of adenomyosis under sedation and analgesia.
【學位授予單位】:重慶醫(yī)科大學
【學位級別】:碩士
【學位授予年份】:2014
【分類號】:R711.71
【參考文獻】
相關期刊論文 前10條
1 高彩芬;王秀麗;李文芳;;米非司酮治療子宮腺肌病30例臨床效果分析[J];中國婦產科臨床雜志;2006年05期
2 鄢利梅;王文亮;何佳;何敏;黃國華;黎克全;張煉;;團塊與整體灰度變化在超聲消融治療子宮腺肌病的意義[J];國際婦產科學雜志;2012年03期
3 陳敏;李鐵軍;陳強;彭松;;高強度聚焦超聲消融子宮腺肌癥的臨床劑量學研究[J];重慶醫(yī)學;2013年20期
4 劉惠蓮;袁中草;劉映文;;丙酸睪丸素和米非司酮聯合治療絕經過渡期功能性子宮出血的臨床效果觀察[J];內蒙古中醫(yī)藥;2009年13期
5 王智彪;;高強度聚焦超聲技術—21世紀的無創(chuàng)醫(yī)療技術[J];微創(chuàng)醫(yī)學;2010年01期
6 吳艷;陳國慶;孫莉;;小劑量米非司酮在子宮腺肌病治療中的臨床療效分析[J];現代預防醫(yī)學;2012年01期
7 王靜波;肖穎麗;張瑩;金瑞林;;腹腔鏡下病灶挖除術治療子宮腺肌病的臨床研究[J];中國內鏡雜志;2011年05期
8 汪偉,劉文英,周潔敏,徐建明,蓋綠華,黃長江;高強度聚焦超聲治療癥狀性子宮肌瘤的初步臨床研究[J];中華超聲影像學雜志;2002年03期
9 張華,顧美皎,王成鑫,黃宏英;子宮腺肌病患者雄激素治療前、后子宮內膜中雌、孕激素受體及表皮生長因子受體的表達[J];中華婦產科雜志;1999年04期
10 王欣;成九梅;段華;;腹腔鏡子宮動脈阻斷聯合子宮腺肌病灶切除對子宮、卵巢血流及內分泌激素的影響[J];中國微創(chuàng)外科雜志;2012年10期
本文編號:2397162
本文鏈接:http://sikaile.net/yixuelunwen/fuchankeerkelunwen/2397162.html